Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

On World Clubfoot Day join our researchers and surgeons for an exhibition and demonstrations at the Nuffield Orthopaedic Centre (NOC). This Friday 3 June you can help us make a difference for children born with clubfoot worldwide. Around 200,000 children each year are born with clubfoot, with around 80% of these in low and middle-income countries.

Around 200,000 children each year are born with clubfoot, with around 80% of these in low and middle-income countries.

If left untreated, clubfoot becomes a painful and severely disabling deformity, where the feet point down and inwards and with the soles of the feet backwards; however, the simple Ponseti treatment is successful in up to 95% of cases, especially if this is initiated early.

NDORMS Professor Chris Lavy has worked with children with clubfoot for the last 30 years, both in the UK and Africa. He currently leads a project that is strengthening training and delivery capacity for clubfoot treatment in 15 sub-Saharan countries - the Africa Clubfoot Training Project.

Read more (Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science (NDORMS) website)

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.

Oxford-led technology to help those at high risk from Covid-19

Coronavirus COVID-19 General Research

More people in England at high risk from Covid-19 will get priority access to vaccines thanks to new technology developed by a University of Oxford-led team of researchers that can identify those who may be most vulnerable to the virus.